Naoko Takebe to Genetic Vectors
This is a "connection" page, showing publications Naoko Takebe has written about Genetic Vectors.
Connection Strength
0.248
-
RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development. Clin Cancer Res. 2008 Jun 15; 14(12):3948-55.
Score: 0.073
-
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002 Mar; 9(3):308-20.
Score: 0.047
-
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001 Dec; 8(12):966-73.
Score: 0.046
-
Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors. Cancer Gene Ther. 2000 Jun; 7(6):910-9.
Score: 0.042
-
Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum Gene Ther. 2003 Mar 20; 14(5):435-46.
Score: 0.013
-
Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol Oncol. 2000 Mar; 76(3):305-10.
Score: 0.010
-
Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Cancer Gene Ther. 1998 May-Jun; 5(3):144-9.
Score: 0.009
-
Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Ther. 1997 Jun; 4(6):570-6.
Score: 0.008